SEC Comment Letter for Item 9 Labs Corp. (INLB) (CIK 0001500123) — Apr 16, 2020
Item 9 Labs Corp. (INLB) (CIK 0001500123)
Date: April 16, 2020 · CIK: 0001500123 · Accession: 0000000000-20-003292
AI Filing Summary & Sentiment
File numbers found in text: 000-54730
Letter
April 15, 2020 Andrew Bowden Chief Executive Officer Item 9 Labs Corp. 2727 North 3rd Street, Suite 201 Phoenix, AZ 85004 Re:Item 9 Labs Corp. Preliminary Information Statement on Schedule 14C Filed March 6, 2020 File No. 000-54730 Dear Mr. Bowden: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jessica M. Lockett, Esq.
Show Raw Text
April 15, 2020
Andrew Bowden
Chief Executive Officer
Item 9 Labs Corp.
2727 North 3rd Street, Suite 201
Phoenix, AZ 85004
Re:Item 9 Labs Corp.
Preliminary Information Statement on Schedule 14C
Filed March 6, 2020
File No. 000-54730
Dear Mr. Bowden:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jessica M. Lockett, Esq.